Drug intelligence / Profile preview

RBX7455

Development stage: Phase 1
Lead developer: Ferring Pharmaceuticals
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

RBX7455 is an investigational, orally administered, lyophilized, room-temperature-stable live biotherapeutic product. [1, 6, 7] It was developed by Rebiotix, which was acquired by Ferring Pharmaceuticals, as a next-generation formulation on their Microbiota Restoration Therapy (MRT) platform. [7, 10, 11] RBX7455 contains a broad consortium of live intestinal microbes derived from healthy human stool and is designed to rehabilitate the gut microbiome. [4, 6] It has been studied in a Phase 1 clinical trial for the prevention of recurrent *Clostridioides difficile* infection (rCDI) and was investigated in a pilot trial for its immunomodulatory effects in patients with operable breast cancer. [1, 4]

Other names: Microbiota-based Formulation RBX7455Oral Microbiota-Based Investigational New Drug

Beyond the preview

Go deeper on RBX7455.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBX7455.

Explore the full profile